Idri And Jubilant Chemsys Extend Research For Tb Drug Discovery

Jubilant Chemsys, a wholly-owned subsidiary of Jubilant Life Sciences, and one of the most recognized drug discovery research services organizations from Asia today announced an extension of collaborative partnership with Infectious Disease Research Institute (IDRI) for TB drug discovery. Today marks World TB Day, designated to build public awareness of the disease. Jubilant Chemsys offers drug discovery research services on Full Time Equivalent and Fees- for-services basis.


 The collaboration in chemistry support has been in existence since 2009 as part of a joint effort with the Lilly TB Drug Discovery Initiative (LTI) and so far has generated hundreds of Novel Chemical Entities (NCEs) “ some of which have now been identified for further exploration. Jubilant Chemsys, under the terms of agreement, so far had been offering philanthropic support and expertise in synthesis of NCEs to support the early research in TB.

 Commenting on the collaboration, Dr. Subir Basak, President, Jubilant Drug Discovery Services Jubilant is excited to extend the partnership with IDRI in identifying and discovering novel chemical entities in the area of tuberculosis. We are glad that the collaboration is leveraging our chemistry talent and our experience in anti-bacterial research. The research outcome will address the current unmet medical need in the field of TB therapy – a growing concern in under developed and developing economies including India.

 We have been impressed with the commitment and engagement from Jubilant Chemsys in support of TB drug discovery over the past few years.  We are excited to expand our efforts with them to access additional synthetic and medicinal chemistry capabilities. This will take us another step closer to our goal of developing much-needed new drugs to combat tuberculosis. Tanya Parish, Ph.D., IDRI, Vice President of Drug Discovery.


 IDRI is a founding member of both the LTI and the TB Drug Accelerator, a unique partnership funded by the Bill & Melinda Gates Foundation that targets the discovery of new TB drugs by collaborating on early-stage research. The Foundation recently awarded IDRI $3.4 million in additional funding to Tanya Parish, Ph.D., IDRI Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million. The grant is focused on identifying new leads and drug targets for tuberculosis with the ultimate goal of producing new drugs to treat TB.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top